Short answer
Kyverna Therapeutics Inc (KYTX) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and business update released for quarter ended September 30, 2026.
Kyverna Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results and business update released for quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for operating metrics, cash position and pipeline developments
Item EX-99.1 · Exhibit EX-99.1
- BLA submission completed for miv-cel in stiff person syndrome, with FDA priority review requested
- Potential 2027 launch would target the first approved SPS therapy and autoimmune CAR-T, creating significant commercial upside if approved
- KYSA-6 Phase 3 gMG enrollment remains on track for mid-2027 completion, extending miv-cel’s late-stage opportunity
- Cash, equivalents and marketable securities $170.6M, with operating runway into 2028 including Oxford Finance facility availability
- Q3 net loss $41.9M, or $0.68 per share, with R&D $27.0M and G&A $15.9M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kyverna Therapeutics Inc 8-K filings
Get the next KYTX 8-K as it lands
Follow KYTX for push alerts, or ask the research agent what this filing means.